ArticlePregnancy (Hoboken, N.J.)2026
Development and validation of a prediction tool to optimize antenatal corticosteroid timing in patients at risk of spontaneous preterm birth.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of this study was to develop and validate a preterm birth (PTB) prediction model to optimize the timing of antenatal corticosteroid (ACS) administration in patients at risk of spontaneous PTB. Methods: Secondary analysis of the nuMoM2b (Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be) prospective cohort study including participants who received ACS due to increased risk for spontaneous PTB (i.e., development cohort). Nulliparous participants presenting between 23 0/7 and 36 6/7 weeks of gestation were eligible for inclusion and were characterized into two groups based on the time interval from the first dose of ACS administration to delivery: ≤7 versus >7 days. Multivariable logistic regression was utilized to assess clinical characteristics at the time of the first dose of ACS administration as candidate predictors for optimal ACS timing, defined as delivery within 7 days of ACS administration. We then externally validated the model using data from patients at risk for spontaneous PTB at two academic centers. The predictive performance of each model was assessed using area under the receiver operating curve (ROC AUC), precision, and recall scores with 95% confidence intervals (CIs). Results: Key predictors for optimal ACS timing were rupture of membranes, cervical dilation and effacement at admission, maternal age, and gravidity. In the development cohort, the model achieved an AUC of 0.84 (95% CI, 0.77-0.92). External validation of these models in two independent cohorts demonstrated consistent performances (AUC, 0.82; 95% CI, 0.75-0.88 and AUC, 0.81; 95% CI, 0.72-0.89). Conclusion: We successfully developed and externally validated a model that predicts whether nulliparas are expected to deliver within 7 days of ACS administration. Further studies can assess whether incorporating this model into clinical practice improves neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.